Abstract
We compared detailed efficacy of efonidipine and nifedipine, dihydropyridine analogues, and mibefradil using recombinant T- and L-type Ca<sup>2+</sup> channels expressed separately in mammalian cells. All these Ca<sup>2+</sup> channel antagonists blocked T-type Ca<sup>2+</sup> channel currents (I<sub>Ca(T)</sub>) with distinct blocking manners: I<sub>Ca(T)</sub> was blocked mainly by a tonic manner by nifedipine, by a use-dependent manner by mibefradil, and by a combination of both manners by efonidipine. IC<sub>50</sub>s of these Ca<sup>2+</sup> channel antagonists to I<sub>Ca(T)</sub> and L-type Ca<sup>2+</sup> channel current (I<sub>Ca(L)</sub>) were 1.2 µmol/l and 0.14 nmol/l for nifedipine; 0.87 and 1.4 µmol/l for mibefradil, and 0.35 µmol/l and 1.8 nmol/l for efonidipine, respectively. Efonidipine, a dihydropyridine analogue, showed high affinity to T-type Ca<sup>2+</sup> channel.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.